Bicara Therapeutics Inc. (BCAX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$19.21−$0.5700 (−2.88%) on the dayAs of the close; data may be delayed.
BCAX price, last 12 months
Key stats
- Previous close
- $19.78
- Open
- $19.86
- Day range
- $19.17 – $19.89
- 52-week range
- $10.48 – $30.99
- Volume
- 662.5K
- Avg volume (20 days)
- 610.2K
- Market cap
- $1.3B
Performance
1W−15.2%
1M−22.3%
3M−28.5%
6M+1.5%
YTD+14.1%
1Y+71.7%
vs S&P 500, 1Y+54.9 pts
Technicals and fundamentals
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.3B